Skip to main content
Premium Trial:

Request an Annual Quote

Skyline Licenses TrovaGene Biomarker for AML

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Skyline Diagnostics has licensed rights to TrovaGene's NPM1 technology in Europe in a microarray test for use in helping guide acute myelogenous leukemia treatment, TrovaGene said today.

Skyline will use the TrovaGene nucleophosmin protein mutation, which is found in around 35 percent of AML patients and is associated with good disease prognosis, in its AMLprofiler in vitro diagnostic assay.

A three-day test, the AMLprofiler is used to reclassify more than 50 percent of intermediate-risk AML patients into favorable or unfavorable risk groups, which helps doctors make treatment decisions. The test combines cytogenetics, mutation analysis, and expression analysis, and replaces nine separate assays, according to San Diego-based TrovaGene.

Netherlands-based Skyline Diagnostics plans to offer the lab testing services in Europe but expects to eventually expand to other markets, TrovaGene said.

Financial terms of the agreement were not released.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.